Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities

About this update from Insulet Corporation

ACTON, Mass., May 05, 2026 --( BUSINESS WIRE )--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the publication of its 2025 Sustainability Report , showcasing progress across its operations, products, people, and community. The report underscores how Insulet’s sustainability strategy continues to strengthen its mission of transforming life for people with diabetes while preserving the health of our planet. "Our sustainability focus is integral to how we advance our mission and deliver solutions that benefit people with diabetes and the planet," said Lisa Brady, Vice President of Global Sustainability and Chief Sustainability Officer. "By expanding access, designing products responsibly, and using resources wisely, we generate positive impact that reaches customers, communities, and the natural world. At the heart of it all is our purpose—helping more people with diabetes experience greater freedom and better health." Key achievements from the 2025 Sustainability Report include: Resilient Operations : Sustainable Product Innovation : People and Communities : The 2025 Sustainability Report can be found on Insulet.com and Investors.Insulet.com/ESG . About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com . ©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260505564581/en/ Contacts Media: Cristal Downing Chief Corporate Affairs Officer [email protected] Investor Relations: Clare Trachtman Vice President, Investor Relations [email protected]

View stock analysis, news, and events for Insulet Corporation